請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69810
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林致廷 | |
dc.contributor.author | Jen-Kuang Lee | en |
dc.contributor.author | 李任光 | zh_TW |
dc.date.accessioned | 2021-06-17T03:28:56Z | - |
dc.date.available | 2018-03-01 | |
dc.date.copyright | 2018-03-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-02-26 | |
dc.identifier.citation | [1] W. H. Organization. 'Health work force: Density of physician,' Sep. 2014; http://gamapserver.who.int/gho/interactive_charts/health_workforce/PhysiciansDensity_Total/atlas.html.
[2] G. J. Kost, “Guidelines for point-of-care testing. Improving patient outcomes,” Am J Clin Pathol, vol. 104, no. 4 Suppl 1, pp. S111-27, Oct, 1995. [3] J. A. DuBois. 'The role of POCT and rapid testing,' Sep, 2013; http://www.mlo-online.com/articles/201309/the-role-of-poct-and-rapid-testing.php. [4] R. H. Birkhahn, E. Haines, W. Wen, L. Reddy, W. M. Briggs, and P. A. Datillo, “Estimating the clinical impact of bringing a multimarker cardiac panel to the bedside in the ED,” Am J Emerg Med, vol. 29, no. 3, pp. 304-8, Mar, 2011. [5] S. Buhrer-Sekula, H. L. Smits, G. C. Gussenhoven, J. van Leeuwen, S. Amador, T. Fujiwara, P. R. Klatser, and L. Oskam, “Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy,” J Clin Microbiol, vol. 41, no. 5, pp. 1991-5, May, 2003. [6] P. D., “Use and limitations of light-microscopy for diagnosing malaria at the primary health-care level,” Bulletin of the World Health Organization, vol. 66, no. 5, pp. 621-626, 1988. [7] B. Kemp, D. Rylatt, P. Bundesen, R. Doherty, D. McPhee, D. Stapleton, L. Cottis, K. Wilson, M. John, J. Khan, and a. et, “Autologous red cell agglutination assay for HIV-1 antibodies: simplified test with whole blood,” Science, vol. 241, no. 4871, pp. 1352-1354, 1988. [8] K. I. Chen, B. R. Li, and Y. T. Chen, “Silicon nanowire field-effect transistor-based biosensors for biomedical diagnosis and cellular recording investigation,” Nano Today, vol. 6, no. 2, pp. 131-154, Apr, 2011. [9] A. Manickam, A. Chevalier, M. McDermott, A. D. Ellington, and A. Hassibi, “A CMOS Electrochemical Impedance Spectroscopy (EIS) Biosensor Array,” IEEE Trans Biomed Circuits Syst, vol. 4, no. 6, pp. 379-90, Dec, 2010. [10] U. Lehmann, M. Sergio, S. Pietrocola, E. Dupont, C. Niclass, M. Gijs, and E. Charbon, “Microparticle photometry in a CMOS microsystem combining magnetic actuation and in situ optical detection,” Sensor Actuator B: Chemical, vol. 132, no. 2, pp. 411-417, 2008. [11] N. Manaresi, A. Romani, G. Medoro, L. Altomare, A. Leonardi, M. Tartagni, and R. Guerrieri, “A cmos chip for individual cell manipulation and detection,” IEEE J Solid-St Circ, vol. 38, no. 12, pp. 2297-2305, 2003. [12] S. Regonda, R. Tian, J. Gao, S. Greene, J. Ding, and W. Hu, “Silicon multi-nanochannel FETs to improve device uniformity/stability and femtomolar detection of insulin in serum,” Biosens Bioelectron, vol. 45, pp. 245-51, Jul 15, 2013. [13] Juan Wang, Guo-Juan Tan, Li-Na Han, Yong-Yi Bai, Miao He, Hong-Bin Liu. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017 Feb; 14(2): 135–150. [14] Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS; Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005 May;51(5):810-24. Epub 2005 Mar 17. [15] Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc. 2017 Mar 13;6(3). pii: e005038. [16] Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000 Oct;21(19):1574-83. [17] Melissa A Daubert, Allen Jeremias. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010; 6: 691–699. [18] Ozturk TC1, Unluer E, Denizbasi A, Guneysel O, Onur O. Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room? J Res Med Sci. 2011 Dec;16(12):1564-71. [19] T. Braun, M. K. Ghatkesar, N. Backmann, W. Grange, P. Boulanger, L. Letellier, H.-P. Lang, A. Bietsch, C. Gerber, and M. Hegner, “Quantitative time-resolved measurement of membrane protein–ligand interactions using microcantilever array sensors,” Nat Nanotechnol, vol. 4, no. 3, pp. 179-185, 2009. [20] C. W. Huang, H. T. Hsueh, Y. J. Huang, H. H. Liao, H. H. Tsai, Y. Z. Juang, T. H. Lin, S. S. Lu, and C. T. Lin, “A fully integrated wireless CMOS microcantilever lab chip for detection of DNA from Hepatitis B virus (HBV),” Sensor Actuat B-Chem, vol. 181, pp. 867-873, May, 2013. [21] P. Bergveld, “Development of an ion-sensitive solid-state device for neurophysiological measurements,” IEEE Trans Biomed Eng, vol. 17, no. 1, pp. 70-1, Jan, 1970. [22] K. Nakazato, “An Integrated ISFET Sensor Array,” Sensors (Basel), vol. 9, no. 11, pp. 8831-51, 2009. [23] P. Bergveld, “Thirty years of ISFETOLOGY - What happened in the past 30 years and what may happen in the next 30 years,” Sensors Actuators B-Chem, vol. 88, no. 1, pp. 1-20, Jan 1, 2003. [24] F. Uslu, S. Ingebrandt, D. Mayer, S. Bocker-Meffert, M. Odenthal, and A. Offenhausser, “Labelfree fully electronic nucleic acid detection system based on a field-effect transistor device,” Biosens Bioelectron, vol. 19, no. 12, pp. 1723-31, Jul 15, 2004. [25] S. V. Dzyadevych, A. P. Soldatkin, A. V. El'skaya, C. Martelet, and N. Jaffrezic-Renault, “Enzyme biosensors based on ion-selective field-effect transistors,” Anal Chim Acta, vol. 568, no. 1-2, pp. 248-58, May 24, 2006. [26] S. Caras, and J. Janata, “Field effect transistor sensitive to penicillin,” Anal Chem, vol. 52, no. 12, pp. 1935-1937, 1980. [27] S. Meyburg, M. Goryll, J. Moers, S. Ingebrandt, S. Bocker-Meffert, H. Luth, and A. Offenhausser, “N-Channel field-effect transistors with floating gates for extracellular recordings,” Biosens Bioelectron, vol. 21, no. 7, pp. 1037-44, Jan 15, 2006. [28] C. Stagni, C. Guiducci, L. Benini, B. Ricco, S. Carrara, C. Paulus, M. Schienle, and R. Thewes, “A fully electronic label-free DNA sensor chip,” IEEE Sens J, vol. 7, no. 3-4, pp. 577-585, Mar-Apr, 2007. [29] S. B. Prakash, and P. Abshire, “Tracking cancer cell proliferation on a CMOS capacitance sensor chip,” Biosens Bioelectron, vol. 23, no. 10, pp. 1449-57, May 15, 2008. [30] P. M. Levine, P. Gong, R. Levicky, and K. L. Shepard, “Real-time, multiplexed electrochemical DNA detection using an active complementary metal-oxide-semiconductor biosensor array with integrated sensor electronics,” Biosens Bioelectron, vol. 24, no. 7, pp. 1995-2001, Mar 15, 2009. [31] J. Bausells, J. Carrabina, A. Errachid, and A. Merlos, “Ion-sensitive field-effect transistors fabricated in a commercial CMOS technology,” Sensors Actuators B-Chem, vol. 57, no. 1-3, pp. 56-62, Sep 7, 1999. [32] W. Y. Chung, Y. T. Lin, D. G. Pijanowska, C. H. Yang, M. C. Wang, A. Krzyskow, and W. Torbicz, “New ISFET interface circuit design with temperature compensation,” Microelectron J, vol. 37, no. 10, pp. 1105-1114, Oct, 2006. [33] P. Bergveld, “The operation of an ISFET as an electronic device,” Sensor Actuator, vol. 1, pp. 17-29, 1981. [34] W. Olthuis, E. Faber, E. Krommenhoek, and A. v. d. Berg, 'Sensing with FETs - once, now and future.' pp. 37-44. [35] F. Patolsky, and C. M. Lieber, “Nanowire nanosensors (vol 8, pg 20, 2005),” Mater Today, vol. 8, no. 5, May, 2005. [36] B. He, T. J. Morrow, and C. D. Keating, “Nanowire sensors for multiplexed detection of biomolecules,” Curr Opin Chem Biol, vol. 12, no. 5, pp. 522-8, Oct, 2008. [37] F. Patolsky, G. Zheng, O. Hayden, M. Lakadamyali, X. Zhuang, and C. M. Lieber, “Electrical detection of single viruses,” Proc Natl Acad Sci U S A, vol. 101, no. 39, pp. 14017-22, Sep 28, 2004. [38] F. Patolsky, B. P. Timko, G. F. Zheng, and C. M. Lieber, “Nanowire-based nanoelectronic devices in the life sciences,” Mrs Bulletin, vol. 32, no. 2, pp. 142-149, Feb, 2007. [39] G. F. Zheng, X. P. A. Gao, and C. M. Lieber, “Frequency Domain Detection of Biomolecules Using Silicon Nanowire Biosensors,” Nano Letters, vol. 10, no. 8, pp. 3179-3183, Aug, 2010. [40] P. R. Nair, and M. A. Alam, “Screening-limited response of nanobiosensors,” Nano Lett, vol. 8, no. 5, pp. 1281-5, May, 2008. [41] C. W. Huang, Y. J. Huang, P. W. Yen, H. H. Tsai, H. H. Liao, Y. Z. Juang, S. S. Lu, and C. T. Lin, “A CMOS wireless biomolecular sensing system-on-chip based on polysilicon nanowire technology,” Lab Chip, vol. 13, no. 22, pp. 4451-9, Oct 15, 2013. [42] Cunningham LD, Conte MS. Lower-extremity arterial disease. Perspect Vasc Surg Endovasc Ther. 2005 Dec;17(4):351-61. [43] Dieter RS, Chu WW, Pacanowski JP Jr, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease. Clin Cardiol. 2002 Jan;25(1):3-10. [44] M. Toner, and D. Irimia, “Blood-on-a-chip,” Annu Rev Biomed Eng, vol. 7, pp. 77-103, 2005. [45] D. Mabey, R. W. Peeling, A. Ustianowski, and M. D. Perkins, “Diagnostics for the developing world,” Nat Rev Microbiol, vol. 2, no. 3, pp. 231-40, Mar, 2004. [46] C. Moore, “Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line?,” J Hosp Infect, vol. 85, pp. 1-7, 2013. [47] Y. Adiguzel, and H. Kulah, “CMOS cell sensors for point-of-care diagnostics,” Sensors vol. 12, no. 8, pp. 10042-66, 2012. [48] K. Seong-Jin, and Y. Euisik, “Label-free CMOS bio sensor with on-chip noise reduction scheme for real-time quantitative monitoring of biomolecules,” IEEE Trans Biomed Circuits Syst, vol. 6, no. 3, pp. 189-96, Jun, 2012. [49] F. Patolsky, B. P. Timko, G. F. Zheng, and C. M. Lieber, “Nanowire-based nanoelectronic devices in the life sciences,” Mrs Bull, vol. 32, no. 2, pp. 142-149, Feb, 2007. [50] E. Stern, J. F. Klemic, D. A. Routenberg, P. N. Wyrembak, D. B. Turner-Evans, A. D. Hamilton, D. A. LaVan, T. M. Fahmy, and M. A. Reed, “Label-free immunodetection with CMOS-compatible semiconducting nanowires,” Nature, vol. 445, no. 7127, pp. 519-22, Feb 1, 2007. [51] E. Stern, A. Vacic, C. Li, F. N. Ishikawa, C. Zhou, M. A. Reed, and T. M. Fahmy, “A nanoelectronic enzyme-linked immunosorbent assay for detection of proteins in physiological solutions,” Small, vol. 6, no. 2, pp. 232-8, Jan, 2010. [52] Y. Y. Song, Y. Li, C. Yang, and X. H. Xia, “Surface electric field manipulation of the adsorption kinetics and biocatalytic properties of cytochrome c on a 3D macroporous Au electrode,” Anal Bioanal Chem, vol. 390, no. 1, pp. 333-41, Jan, 2008. [53] Y. K. Yen, C. Y. Huang, C. H. Chen, C. M. Hung, K. C. Wu, C. K. Lee, J. S. Chang, S. M. Lin, and L. S. Huang, “A novel, electrically protein-manipulated microcantilever biosensor for enhancement of capture antibody immobilization,” Sensors Actuators B-Chem, vol. 141, no. 2, pp. 498-505, Sep 7, 2009. [54] A. H. B. Wu, F. S. Apple, W. B. Gibler, R. L. Jesse, M. M. Warshaw, and R. Valdes, “National Academy of Clinical Biochemistry standards of laboratory practice: Recommendations for the use of cardiac markers in coronary artery diseases,” Clin Chem, vol. 45, no. 7, pp. 1104-1121, Jul, 1999. [55] E. M. Ohman, P. W. Armstrong, R. H. Christenson, C. B. Granger, H. A. Katus, C. W. Hamm, M. A. O'Hanesian, G. S. Wagner, N. S. Kleiman, F. E. Harrell, Jr., R. M. Califf, and E. J. Topol, “Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators,” N Engl J Med, vol. 335, no. 18, pp. 1333-41, Oct 31, 1996. [56] J. H. Chua, R. E. Chee, A. Agarwal, S. M. Wong, and G. J. Zhang, “Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays,” Anal Chem, vol. 81, no. 15, pp. 6266-71, Aug 1, 2009. [57] T. Kong, R. Su, B. Zhang, Q. Zhang, and G. Cheng, “CMOS-compatible, label-free silicon-nanowire biosensors to detect cardiac troponin I for acute myocardial infarction diagnosis,” Biosens Bioelectron, vol. 34, no. 1, pp. 267-72, Apr 15, 2012. [58] J. Li, Y. Zhang, S. To, L. You, and Y. Sun, “Effect of nanowire number, diameter, and doping density on nano-FET biosensor sensitivity,” ACS Nano, vol. 5, no. 8, pp. 6661-8, Aug 23, 2011. [59] P. R. Nair, and M. A. Alam, “Design considerations of silicon nanowire biosensors,” IEEE T Electron Dev, vol. 54, no. 12, pp. 3400-3408, Dec, 2007. [60] K. K. N. Simon M. Sze, Physics of Semiconductor Devices, 2nd ed., New York: John Wiley & Sons, 2006. [61] T. Hianik , V. Ostatná, M. Sonlajtnerova, and I. Grman, “Influence of ionic strength, pH and aptamer configuration for binding affinity to thrombin”, Bioelectrochemistry , vol. 70,pp. 127–133, 2007 [62] P. F. Strang, and J. D. Potter, “A Monoclonal-Antibody That Recognizes Different Conformational States of Skeletal-Muscle Troponin-C and Other Calcium-Binding Proteins,” J Muscle Res Cell Motil, vol. 13, no. 3, pp. 308-314, Jun, 1992. [63] Peronnet, E.; Becquart, L.; Martinez, J.; Charrier, J.P.; Jolivet-Reynaud, C. Isoelectric point determination of cardiac troponin I forms present in plasma from patients with myocardial infarction. Clin. Chim. Acta 2007, 377, 243–247. [64] 23. Ma, X.; Chen, Z.; Zheng, H.; Huang, B.; Cai, L. Interleukin-6 gene cloning, expression and purification. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Acad. Med. Sin. 1998, 20, 185–190. [65] Hideshima, S.; Sato, R.; Kuroiwa, S.; Osaka, T. Fabrication of stable antibody-modified field effect transistors using electrical activation of Schiff base cross-linkages for tumor marker detection. Biosens. Bioelectron. 2011, 26, 2419–2425. [66] Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101, 1767–1772. [67] 28. Wu, C.K.; Lee, J.K.; Chiang, F.T.; Yang, C.H.; Huang, S.W.; Hwang, J.J.; Lin, J.L.; Tseng, C.D.; Chen, J.J.; Tsai, C.T. Plasma levels of tumor necrosis factor- and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit. Care Med. 2011, 39, 984–992. [68] Lin, C.Y.; Wu, C.K.; Yeong, E.K.; Lin, H.H.; Huang, Y.T.; Lee, J.K.; Lin, Y.H.; Chiang, F.T.; Tang, Y.B.; Tsai, C.T. Prognostic significance of left ventricular diastolic function in burn patients. Shock 2012, 37, 457–462. [69] Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Simoons, M.L.; Chaitman, B.R.; White, H.D. Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33, 2551–2567. [70] Morrow, D.A.; Cannon, C.P.; Jesse, R.L.; Newby, L.K.; Ravkilde, J.; Storrow, A.B.; Wu, A.H.B.; Christenson, R.H. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. J. Clin. Chem. 2007, 53, 552–574. [71] Maisel, A.; Mueller, C.; Adams, K., Jr.; Anker, S.D.; Aspromonte, N.; Cleland, J.G.F.; Cohen-Solal, A.; Dahlstrom, U.; DeMaria, A.; Di Somma, S.; et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 2008, 10, 824–839. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69810 | - |
dc.description.abstract | 個人化醫療在近年來一直是一個非常重要的議題,利用床邊檢驗幫助臨床醫師與病患治療疾病,隨著科技的發展,有越來越多的工具可以使用。另一方面,對於醫師資源短缺的地區或國家來說,使用此床邊檢驗可以幫助未能親自前往的醫師幫忙診斷及重症疾病,進而做醫療決策轉送至後邊大型醫院接受治療,個人醫療診斷平台開發越益重要且其具有相當大的潛力。另一方面,由於全球半導體技術快速的成熟及發展,我們可以進一步利用CMOS平台開發個人醫療體外診斷系統,為未來主要研究發展方向。
根據美國心臟病協會(American Heart Association, AHA) 的調查顯示,在美國每三個人之中就有一個人會死於心血管疾病:包括冠狀動脈硬化、心律不整、心肌梗塞、中風等。臨床資料顯示,目前台灣的心血管相關疾病的罹患比率已經和美國相去不遠,主要和生活習慣已逐漸西化有關,常見的抽菸、不規律的運動、飲食習慣不良等都會增加罹患的風險。預防心血管疾病的發生,首先就是要先了解引發的因子。現代人的心血管疾病大多是因為冠狀動脈病變所引起,在臨床上,心血管疾病的血清標記在救治病人與時效性方面的意義都非常的重要。重要的心血管疾病包括了冠狀動脈疾病,心肌梗塞,與心臟衰竭。此三種疾病都有對應的血清標記,若能早期偵測,早期預防,不良心血管事件與死亡率皆能大幅降低與改善。在臨床上,這些心血管血清標記已被大幅使用於診治病人,但是它們的準確性與敏感度仍然是科學界努力的目標。 本論文除了對生醫系統單晶片診斷平台的設計做一完整介紹外,也將介紹所開發系統單晶片並且實際應用於臨床血液檢體樣本。此系統單晶片分別為高靈敏度生物分子感測系統,並可同時檢測三種重要的血清標記,用以診斷嚴重的心血管疾病與其臨床預後。以下為所研發之生醫系統單晶片的摘要介紹: 高靈敏度Biodiagnosis system-on-chip (BioSSoC)臨床血清樣本檢測系統單晶片 利用台積電0.35 μm製程技術,實現具高靈敏度之臨床血清樣本檢測單晶片,可針對心血管疾病,急性心肌梗塞,與心臟衰竭,檢測相對應的interleukin-6、cardiac Tropnin-I和N-termianl proBNP。對於個人醫療診斷而言,如何正確而即時檢測血液中三種指標蛋白濃度為現今研究主要面對課題。在此系統單晶片設計上整合了CMOS矽奈米線元件,搭配低雜訊高CMRR的特性介面電路,針對臨床血清樣本實現一矽奈米線心血管疾病特異蛋白組件檢測SoC晶片系統。經由實驗結果證實,interleukin-6、cardiac Tropnin-I和N-terminal proBNP在稀釋的血清樣本中,仍能有效偵測此三種血清蛋白。此結果顯示BioSSoC在臨床血清樣本中仍具有感測高靈敏度,十分適合為個人醫療體外診斷應用。 | zh_TW |
dc.description.abstract | Doctor shortage remains a critical problem across the world. To solve this issue, point-of-care testing (POCT) platform shows significant potential in diagnostic function, owing to its merits in clinical healthcare application. Among various POCT devices, in vitro diagnosis (IVD) for clinical blood test is the most critical field for POCT development. Harnessing the advantages of complementary metal-oxide-semiconductor(CMOS) technology, CMOS-based biomedical system has great potential to realize the vision of future POCT platform system. In this dissertation, a complete overview of POCT was first given, followed by introduction of CMOS-based biosensors for bio-diagnosis system. The bio-diagnostic system consisted of clinical blood sampler and silicon-based sensor device. It could serve as a SoC sensor product for POCT personal healthcare application. The CMOS SoCs was implemented and designed for biomolecular detection and biosample diagnosis platform.
According to the American Heart Association (AHA) survey, one out of every three people in the United States dies of cardiovascular disease: coronary atherosclerosis, myocardial infarction, stroke, and more. Clinical data show that at present the incidence of cardiovascular-related diseases in Taiwan is not far from the United States. It is mainly due to the gradual westernization of living habits. Common smoking, irregular exercise and poor eating habits all increase the risk of cardiovascular disease. Prevent the occurrence of cardiovascular disease, the first is to first understand the trigger factor. Modern cardiovascular diseases are mostly caused by coronary artery lesions. In clinical practice, the significance of serum markers of cardiovascular diseases in the treatment of patients and the timeliness are very important. Important cardiovascular diseases include coronary artery disease, myocardial infarction, and heart failure. All three diseases have corresponding serum markers. If early detection, early prevention, adverse cardiovascular events and mortality can be significantly reduced and improved. Clinically, these cardiovascular serum markers have been widely used in the diagnosis and treatment of patients, but their accuracy and sensitivity remain the goal of the scientific community. The chip was the biodiagnosis system-on-chip (BioSSoC) for biomarker detection in clinical serum samples. In blood test application, the biomolecular analyses in serum provided essential information to diagnose patient status. For the development of the POCT blood diagnosis device, this BioSSoC presented a poly-silicon nanowire (poly-Si NW) biosensor SoC implemented in a 0.35μm CMOS process from a semiconductor foundry. The biosensor SoC could respond to three biomarkers of cardiac disease in phantom serum samples. The enhancement could be contributed to the electrostatic interaction among target biomolecules. This was the first time for a fully integrated poly-Si NW CMOS biosensor to demonstrate feasibility of biomarker detection in serum samples. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:28:56Z (GMT). No. of bitstreams: 1 ntu-107-D98945003-1.pdf: 5451278 bytes, checksum: c273c3e9f47acfa29b7918a71ea4e029 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………………………………………………...2
誌謝…………………………………………………………………………………...3 中文摘要……………………………………………………………………………...4 ABSTRACT..……………..…………………………………………………………..6 CONTENT……………………………………………………………………………8 LIST of FIGURES…………………………………………………………………..10 LIST of TABLES……………………………………………………………………12 1 Introduction………………………………………………………………….…13 1.1 Introduction of Point-of-care testing (POCT)…………………………………………….13 1.2 Development of POCT device……………………………………………………………14 1.3 The objective of this dissertation: CMOS SoC POCT platform………………………....16 1.4 Realization of CMOS-based bio-diagnosis SoC technology for clinical blood test application………………………………………………………………………………..17 1.5 The organization of this dissertation……………………………………………………..18 2 Literature review………………………………………………………….……20 2.1 Biomarkers for heart disease……………………………………………………………..20 2.1.1 Interleukin-6 for vascular inflammation…………………………………………...21 2.1.2 Cardiac Troponin-I for acute myocardial infarction……………………………….23 2.1.3 N-termial proBNP for congestive heart failure…………………………………….24 2.2 The silicon-based ultrasensitive biosensors……………………………………………...26 2.2.1 Microelectromechanical cantilever…………………………………….…………..26 2.2.2 ISFET (ion-sensitive field effect transistor)…………………………………….….28 2.2.3 SiNW FET (Silicon Nanowire Field Effect Transistor)………………....................32 3 Validate the clinical importance of cardiac biomarkers……………….……39 3.1 Patients with lower extremity arterial disease……………………………………………39 3.2 Patient selection…………………………………………………………………………..40 3.3 Interleukin-6 and the severity of coronary artery disease………………………………...41 3.4 Cardiac Troponin-I and major adverse cardiovascular event…………………………….42 3.5 N-terminal proBNP and hospitalization for heart failure………………………………...43 4 Develop the SiNW biosensor SoC for clinical serum detection……………..44 4.1 The clinical POCT device for blood serum test………………………………………….44 4.2 Materials and methods……………………………………………………………………45 4.2.1 Chemical reagents and serum biomarkers…………………………………………45 4.2.2 System design and implementation of BioSSoC…………………………………..46 4.2.3 Surface function of Poly-SiNW……………………………………………………51 4.2.4 Experimental protocol and measurement procedure…………………………….....52 4.3 Results…………….……………………………………………………………………...53 4.3.1 BioSSoC experimental result………………………………………………………..53 4.3.2 Measurement of biomarkers in buffer solutions…………………………………….54 4.3.3 Measurement of biomarkers in human serums……………………………………...55 4.4 Discussion………………………………………………………………………………...58 4.5 Conclusion………………………………………………………………………………..61 5 Conclusion……………………………………………………………………....63 Reference……………………………………………………………………………64 | |
dc.language.iso | en | |
dc.title | 利用CMOS生物感測技術檢驗臨床心臟疾病的血清生物分子 | zh_TW |
dc.title | Biomolecular analysis for clinical heart disease diagnosis
based on CMOS biosensing technologies | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 江福田,何奕倫,宋孔彬,黃念祖,陳奕帆 | |
dc.subject.keyword | 系統單晶片,CMOS 個人醫療診斷平台,矽奈米線,生物分子檢測, | zh_TW |
dc.subject.keyword | SoC,CMOS-based POCT,Poly-SiNW,Biomarker detection,Whole blood sample, | en |
dc.relation.page | 71 | |
dc.identifier.doi | 10.6342/NTU201800620 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-02-26 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 5.32 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。